Clinical Trials Sponsored by Galapagos NV

Total 332 results

Galapagos NV

Recruiting

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) (GALOCEAN)

Ulcerative Colitis

Belgium, Netherlands, France, Italy, Germany, Norway, United Kingdom, Ireland, Austria
Galapagos NV

Completed

First-in-Human Single Ascending Dose of GLPG0492

Healthy

Belgium
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Healthy

Germany
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Healthy

Germany
Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

Healthy | Psoriasis

Belgium, Moldova, Republic of, Ukraine
Galapagos NV

Completed

A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970

Healthy

France
Galapagos NV

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects

Healthy

United States
Galapagos NV

Completed

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Rheumatoid Arthritis

New Zealand, Colombia, Australia, Romania, United States, Bulgaria, Germany, Latvia, Mexico, Moldova, Republic of, Poland, Spain, Argentina, Austria, Chile, Guatemala, Hungary, Russian Federation, Ukraine
Galapagos NV

Completed

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) (DARWIN1)

Rheumatoid Arthritis

France, Spain, New Zealand, Belgium, Israel, Chile, United States, Colombia, Germany, Australia, Poland, Hungary, Russian Federation, Mexico, Argentina, Bulgaria, Czechia, Guatemala, Latvia, Moldova, Republic of, Ukraine, Austria
Galapagos NV

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United Kingdom, Ukraine
Galapagos NV

Terminated

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Healthy | Atopic Dermatitis

Spain, Germany, Ukraine, United Kingdom
Galapagos NV

Completed

A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines

Healthy

United Kingdom
Galapagos NV

Completed

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

Healthy

United Kingdom
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
Galapagos NV

Completed

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Cystic Fibrosis

Belgium
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Healthy

Netherlands
Galapagos NV

Completed

A Study With GLPG1972 in Osteoarthritis Subjects

Osteoarthritis

United States
Galapagos NV

Completed

Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Healthy

Belgium
Galapagos NV

Terminated

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Clinically Isolated Syndrome | Acute Exacerbation of Remitting Relapsing Multiple Sclerosis

Belgium, Poland, Germany
Galapagos NV

Completed

A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

Healthy

Belgium
Galapagos NV

Completed

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Crohn's Disease

United Kingdom, Belgium, France, Hungary, Russian Federation, Czech Republic, Germany, Poland, Romania
Galapagos NV

Completed

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (ORIGIN)

Ulcerative Colitis

Belgium, Czech Republic, Germany, Hungary, Poland, Russian Federation
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1837

Healthy

Belgium
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Healthy

United Kingdom
Galapagos NV

Completed

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Renal Impairment

Germany
Galapagos NV

Completed

Oral Bioavailability of Two Solid Formulations of GLPG0634

Healthy

Belgium
Galapagos NV

Completed

GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors

Solid Tumors

Netherlands
Galapagos NV

Completed

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

Healthy

United States
Galapagos NV

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects

Healthy

Belgium
Galapagos NV

Completed

Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers

Healthy

Belgium
Galapagos NV

Completed

GLPG0492 Pharmacodynamics

Healthy

Belgium
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects

Healthy

Germany
Galapagos NV

Completed

Oral Bioavailability of GLPG0555 in Different Solid Formulations

Healthy

Belgium
Galapagos NV

Completed

GLPG0259 Solid Formulation Bioavailability and Food Effect

Healthy

Belgium
Galapagos NV

Recruiting

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Juvenile Idiopathic Arthritis

United Kingdom, France, Germany
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)

Systemic Lupus Erythematosus

United States, Spain, Bulgaria, France, Georgia, Argentina, Poland, Hungary, Germany, Chile
Galapagos NV

Recruiting

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (FILOSOPHY)

Rheumatoid Arthritis

Belgium, Germany, Spain, Italy, United Kingdom, Netherlands
Galapagos NV

Terminated

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission (CAPYBARA)

Ulcerative Colitis

United States, Germany, Korea, Republic of, Spain, France, Hungary, United Kingdom, Poland, Belgium, Czechia, Italy, South Africa, Taiwan
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis (SEA TURTLE)

Ulcerative Colitis

Ukraine, Georgia, Poland, Moldova, Republic of
Galapagos NV

Terminated

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA1)

Idiopathic Pulmonary Fibrosis

United States, Spain, Japan, Belgium, Taiwan, Denmark, Germany, United Kingdom, Greece, Australia, Czechia, Brazil, Chile, Peru, Turkey
Galapagos NV

Terminated

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA2)

Idiopathic Pulmonary Fibrosis

United States, Netherlands, Korea, Republic of, Israel, Japan, New Zealand, France, Italy, Argentina, Germany, Hungary, South Africa, Poland, Canada, Mexico
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

Rheumatoid Arthritis

Ukraine, Georgia, Bulgaria, Poland
Galapagos NV

Completed

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Healthy

United Kingdom
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Healthy

Canada
Galapagos NV

Completed

A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) (PINTA)

Idiopathic Pulmonary Fibrosis

Slovakia, Finland, France, Sweden, Bulgaria, Croatia, Oman, Romania, Ukraine
Galapagos NV

Completed

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

Healthy

United Kingdom
Galapagos NV

Completed

Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205

Healthy

United Kingdom
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects

Healthy

United Kingdom
Galapagos NV

Terminated

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis (GECKO)

Atopic Dermatitis

United States
Galapagos NV

Completed

A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases

Healthy

Netherlands

3

Subscribe